Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB220 is a recombinant enzyme product developed by Proteos Biotech, consisting of Collagenase G and Collagenase H derived from *Clostridium histolyticum*. Produced via recombinant DNA technology in bacterial systems, it functions as a proteolytic enzyme that specifically targets and degrades non-functional or amorphous collagen fibers within the extracellular matrix. This mechanism facilitates the remodeling of connective tissue, making it effective for treating pathological collagen accumulation in scars, post-surgical fibrosis, and striae (stretch marks). Marketed under the PBSerum brand, it is also utilized in aesthetic medicine for facial, periocular, and hand rejuvenation to improve skin health and texture. The enzyme is typically provided in a lyophilized form to maintain stability and activity without the need for preservatives.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PB220.